814 reports of this reaction
4.0% of all NADOLOL reports
#2 most reported adverse reaction
MACULAR DEGENERATION is the #2 most commonly reported adverse reaction for NADOLOL, manufactured by Alembic Pharmaceuticals Inc.. There are 814 FDA adverse event reports linking NADOLOL to MACULAR DEGENERATION. This represents approximately 4.0% of all 20,171 adverse event reports for this drug.
Patients taking NADOLOL who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is moderately reported among NADOLOL users, representing a notable but not dominant share of adverse events.
In addition to macular degeneration, the following adverse reactions have been reported for NADOLOL:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 814 FDA reports for NADOLOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 4.0% of all adverse event reports for NADOLOL, making it one of the most commonly reported side effect.
If you experience macular degeneration while taking NADOLOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.